Sponsors / EBS
EBS

Emergent BioSolutions

Company identity has not yet been verified

See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.

Follow company
13Trials in this database
1Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated AdultsNCT00053482Emergent BioSolutionsPhase 2Completed2003-04Actual
Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox VaccinationNCT00053495Emergent BioSolutionsPhase 2Completed2003-06Actual
Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy AdultsNCT00679172Emergent BioSolutionsPhase 2Completed2008-12Actual
HuMax-CD4 in Non-Cutaneous T-Cell LymphomaNCT00877656Emergent BioSolutionsPhase 2, Phase 3Completed2006-01Actual
CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell LymphomaNCT00893516Emergent BioSolutionsPhase 2Terminated2008-10Actual
VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIVNCT01158157Emergent BioSolutionsPhase 3Completed2012-02-14Actual
Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)NCT01311674Emergent BioSolutionsPhase 3Terminated2011-03-11Actual
Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy AdultsNCT01491607Emergent BioSolutionsPhase 3Completed2012-05Actual
Ciprofloxacin BioThrax Co-Administration StudyNCT01753115Emergent BioSolutionsPhase 2Completed2013-08Actual
A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose LevelsNCT01770743Emergent BioSolutionsPhase 2Completed2014-02Actual
Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza ANCT03315104Emergent BioSolutionsPhase 2Completed2019-06-17Actual
VELOCITY: An Anthrax Vaccine Clinical StudyNCT03877926Emergent BioSolutionsPhase 3Completed2020-08-06Actual
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical StudyNCT04067011Emergent BioSolutionsPhase 2Completed2020-03-05Actual

Latest recorded trial changes